The therapeutic potential of novel aromatase inhibitors in breast cancer

Bibliography

• SLUIJMER AV, HEINEMAN MJ, DE JONG FH, EVERS JLH:Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorec-tomy. J. Clin. Endocrinol. Metab. (1995) 80:2163–2167.
   PubMed Web of Science ®Google Scholar
• THE EARLY BREAST CANCER TRIALISTS COLLABORATIVEGROUP: Tamoxifen for early breast cancer: an over-view of the randomised trials. Lancet (1998) 351:1451–1467.
   PubMed Web of Science ®Google Scholar
• FISHER B, CONSTANTINO JP, REDMOND CK et al: En-dometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. (1994) 86:527–537.
   PubMed Web of Science ®Google Scholar
• DEFRIEND DJ, ANDERSON E, BELL J et al: Effects of 4-hydroxytamoxifen and a pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br. J. Cancer (1994) 70:204–211.
   PubMed Web of Science ®Google Scholar
• HOWELL A, CLARKE RB, ANDERSON E: Response after withdrawal of tamoxifen and progestagens in ad-vanced breast cancer. Ann. Oncol. (1992) 3:611–617.
   PubMed Web of Science ®Google Scholar
• MILLER WR: Aromatase inhibitors. Endocr. Rel. Cancer(1996) 3:65–79.
   Web of Science ®Google Scholar
• LONNING PE: Aromatase inhibitors and their futurerole in post-menopausal women with early breast can-cer. Br. J. Cancer (1998) 78 (4):12–15.
   PubMedGoogle Scholar
• •A recent and interesting review of aromatase inhibitors.
   Google Scholar
• GEISLER J, KING N, DOWSETT M et al.: Influence of anas-trozole (Arimidex), a selective, non-steroidal aro-matase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer (1996) 74:1286–1291.
   PubMed Web of Science ®Google Scholar
• DEMERS LM: Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res. Treat. (1994) 30:95–102.
   PubMed Web of Science ®Google Scholar
• GEISLER J, KING N, ANKER G et al.: In vivo inhibition of aromatization by exemestane, a novel irreversible aro-matase inhibitor, in postmenopausal breast cancer pa-tients. Clin. Cancer Res. (1998) 4:2089–2093.
   PubMed Web of Science ®Google Scholar
• BRODIE A, LONG B, LU Q: Aromatase expression in the human breast. Breast Cancer Res. Treat. (1998) 49:S85–S91.
   PubMed Web of Science ®Google Scholar
• MILLER WR, TELFORD J, SMITH H, DIXON JM: Effect of neoadjuvant treatment with the aromatase inhibitor letrozole on peripheral synthesis of oestrogen, uptake by the breast and in situ production of oestrogen within mammary tissues. Breast Cancer Res. Treat. (1998) 50:228.
   Google Scholar
• TILSON-MALLETT N, SANTER SJ, FEIL PD et al.: Biological significance of aromatase activity in human breast tu-mours. J. Clin. Endocrinol. Metab. (1983) 57:1125–1128.
   PubMed Web of Science ®Google Scholar
• ROSE C, FREUE M, KJAER M et al.: An open, comparative randomized trial comparing formestane vs. oral megestrol acetate as a second-line therapy inpostmenopausal advanced breast cancer patients. Eur. J. Cancer (1995) 31 (5):S76.
   Google Scholar
• THeRLIMANN B, CASTIGLIONE M, HSU-SCHMITZ SF et al: Formestane versus megestrol acetate in postmeno-pausal breast cancer patient after failure of tamoxifen: a Phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur. J. Cancer (1997) 33:1017–1024.
   PubMed Web of Science ®Google Scholar
• PÉREZ CARRION R, CANDEL V, CALABRESI F et al.: Com-parison of the selective aromatase inhibitor formes-tane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann. Oncol. (1994) 5 (7):S19–S24.
   PubMedGoogle Scholar
• BAJETTA E, ZILEMBO N, NOBERASCO C et al.: Antitu-mour activity of two doses of formestane as first line treatment of advanced breast cancer (ABC). Proc. ASCO (1996) 15:110.
   Google Scholar
• THeRLIMANN B, PARIDAENS R, SERIN D eta].: Third-line hormonal treatment with exemestane in postmeno-pausal patients with advanced breast cancer progress-ing on aminoglutethimide: a Phase II multicentre multinational study. Exemestane Study Group. Eur. J. Cancer (1997) 33:1767–1773.
   Google Scholar
• LONNING PE, BAJETTA E, MURRAY R et al: A Phase IIstudy of exemestane (exe) in metastatic breast cancer (MBC) patients failing non steroidal aromatase inhibi-tors (ns-AIs). Breast Cancer Res. Treat (1998) 50:304.
   Google Scholar
• KVINNSLAND S, ANKER G, DIRIX LY etal. Activity of exe-mestane, an irreversible, oral aromatase inhibitor in metastatic postmenopausal breast cancer patients fail-ing tamoxifen. Eur. J. Cancer (1998) 34 (5):591.
   Google Scholar
• BUZDAR AU, SMITH R, VOGEL C et al.: Fadrozole HCL(CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carci-noma: results of two randomized double blind con-trolled multiinstitutional trials. Cancer (1996) 77:2503–2513.
   PubMed Web of Science ®Google Scholar
• BEZWODA WR, GUDGEON A, FALKSON G, JORDAAN JP, GOEDHALS L: Fadrozole versus megestrol acetate: a double-blind randomised trial in advanced breast can-cer. Oncology 1998, 55:416–420.
   PubMed Web of Science ®Google Scholar
• THeRLIMANN B, BERETTA K, BACCHI M et al.: First-line fadrozole HC1 (CGS 16949A) versus tamoxifen in post-menopausal women with advanced breast cancer. Pro-spective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann. Oncol (1996) 7:471–479.
   Google Scholar
• FALKSON CI, FALKSON HC: A randomised study of CGS16949A (fadrozole) versus tamoxifen in previously un-treated postmenopausal patients with metastatic breast cancer. Ann. Oncol. (1996) 7:465–469.
   PubMed Web of Science ®Google Scholar
• SMITH IE, NORTON A: Fadrozole and letrozole in ad-vanced breast cancer: clinical and biochemical effects. Breast Cancer Res. Treat. (1998) 49 (1):567–571.
   Google Scholar
• PLOURDE PV, DYROFF M, DUKES M: Arimidex: a potentand selective fourth generation aromatase inhibitor. Breast Cancer Res. Treat. (1994) 30:103–111.
   PubMed Web of Science ®Google Scholar
• BUZDAR A, JONAT W, HOWELL A et al.: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with ad-vanced breast cancer: results of overview analysis of two Phase III trials. Arimidex Study Group. J. Clin. On-col. (1996) 14:2000–2011.
   Google Scholar
• ••A large trial, updated results of which show superior efficacyof an aromatase inhibitor to progestins for the first time.
   Google Scholar
• BUZDAR AU, JONAT W, HOWELL A et al.: Anastrozole versus megestrol acetate in the treatment of post-menopausal women with advanced breast carcinoma: results of a survival update based on a combined analy-sis of data from two mature Phase III trials. Arimidex Study Group. Cancer (1998) 83:1142–1152.
   Google Scholar
• ••Updated results of the above study.
   Google Scholar
• HOWELL A, DEFRIEND D, ROBERTSON J, BLAMEY R, WALTON P: Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet (1995) 345:29–30.
   PubMed Web of Science ®Google Scholar
• MURRAY R, VAN ZYL J, GUDGEON A et al. Rivizor ver- sus aminoglutethimide in the second-line treatment of advanced postmenopausal breast cancer. Ann. On-col (1996) 7 (5):18.
   Google Scholar
• BERGH J, BONNETERRE J, ILLIGER HJ et al.: Vorozole(Rivizor') versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen. Proc. ASCO (1997) 16:155a.
   Google Scholar
• GOSS P, WINE E, TANNOCK I et al.: Vorozole versusMegace® in postmenopausal patients with metastatic breast carcinoma who had relapsed following ta-moxifen. Proc. ASCO (1997) 16:155a.
   Google Scholar
• INGLE JN, JOHNSON PA, SUMAN VJ et al.: A randomisedPhase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer (1997) 80:218–224.
   PubMed Web of Science ®Google Scholar
• GERSHANOVICH M, CHAUDRI HA, CAMPOS D et al.: Letrozole, a new oral aromatase inhibitor; randomised trial comparing 2.5 mg daily, 0.5 mg daily and amino-glutethimide in postmenopausal women with ad-vanced breast cancer. Ann. Oncol. (1998) 9:639–645.
   Google Scholar
• DOMBERNOWSKY I, SMITH I, FALKSON G et al.: Letro-zole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. (1998) 16:453–461.
   PubMed Web of Science ®Google Scholar
• ••Another trail showing improved efficacy and tolerability ofan aromatase inhibitor compared to megestrol acetate in ad-vanced breast cancer.
   Google Scholar
• GARDIN G, FORNASIERO A, ROMIEU G et al.: Long dura- tion of response with letrozole 2.5 mg (Femara® ) in two trials in postmenopausal women with advanced breast cancer after anti-estrogen therapy. Eur. J. Cancer (1998) 34 (5):513. SMITH IE: Pivotal trials of letrozole: a new aromatase inhibitor. Oncology (Huntingt.) (1998) 12:41-44. A recent review of the key trials of letrozole. STEIN RC, DOWSETT M, HEDLEY A et al.: The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br. J. Cancer (1990) 62:679–683.
   Google Scholar
• CELIO L, MARTINETTI A, FERRARI L et al.: The LHRH ana- logue triptoreline (TRP) with or without the aromatase inhibitor formestane (4–0HA) in premenopausal ad-vanced breast cancer: A study by the I.T.M.O.group. Eur. J. Cancer (1998) 33 (8):5155.
   Google Scholar
• KLIJN JGM, BLAMEY RW, BOCCARDO F et al.: Combina- tion LHRH-agonist plus tamoxifen treatment is supe-rior to medical castration alone in premenopausal metastatic breast cancer: a subgroup and meta-analysis of the combined hormonal agents trialists group (CHAT). Breast Cancer Res. Treat. (1998) 50:227.
   PubMedGoogle Scholar
• KAUFMANN M, VON MINCKWITZ G: New Hormones. In: Textbook of breast cancer, Bonadonna G, Hortobagyi G, Gi-anni AM Dunitz (Eds.), Martin Dunitz, London (1997):299.
   Google Scholar
• ZACCHEO T, GIUDICI D, DI SALLE E: Inhibitory effect of combined treatment with the aromatase inhibitor exe-mestane and tamoxifen on DMBA-induced mammary tumours in rats. J. Steroid. Biochem. Mol. Biol. (1993) 44:677–680.
   PubMed Web of Science ®Google Scholar
• BAUM M, HOUGHTON J: Arimidex, tamoxifen alone orin combination (ATAC) adjuvant trial in post-menopausal breast cancer. Eur. J. Cancer (1998) 34 (1):S39.
   Google Scholar
• DOWSETT M, TOBIAS JS, HOWELL A et al.: The effect ofanastrozole on the pharmacokinetics of tamoxifen in postmenopausal women with early breast cancer. Br. J. Cancer (1999) (In Press).
   Google Scholar
• LUNDGREN S, DONNING PE, AAKVAAG A, KVINNSLANDS: Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol ace-tate in postmenopausal patients with advanced breast cancer. Cancer Chemother. Pharmacol. (1990) 27:101–105.
   PubMed Web of Science ®Google Scholar
• LIEN EA, ANKER G, DONNING PE, SOLHEIM E, UELANDPM: Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. (1990) 50:5851–5857.
   PubMed Web of Science ®Google Scholar
• BOCCARDO F, RUBAGOTTI A, AMOROSO D: Review ofItalian breast cancer study group (GROCTA) trials. Eur. J. Cancer (1998) 34 (1):S11.
   Google Scholar
• TAYLOR P, CLARKE, ANDERSON E, HOWELL A: Wheredoes primary endocrine therapy currently stand in breast cancer management? CME Oncology (1998) 1:10–12.
   Google Scholar
• DIXON JM, LOVE CBD, TUCKER S: Letrozole as primarymedical therapy for locally advanced and large oper-able breast cancer. Breast Cancer Res. Treat. (1997) 46:54.
   Google Scholar
• •A very interesting study which suggests letrozole may be su-perior to tamoxifen in this setting, although non-randomised.
   Google Scholar
• LUBET RA, STEELE VE, CASEBOLT TL: Chemopreventiveeffects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitro-surea (MNU)-induced mammary tumour model in Spague-Dawley rats. Carcinogenesis (1994) 15:2775–2780.
   PubMed Web of Science ®Google Scholar
• MURRAY R, PITT P: Aromatase inhibition with 4-0Handrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res. Treat. (1995) 35:249–253.
   PubMed Web of Science ®Google Scholar
• GEISLER J, JOHANNESSEN DC, ANKER G, LONNING PE:Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects. Eur. J. Cancer (1996) 32a:789–792.
   Google Scholar
• DOWSETT M: Theoretical considerations for the idealaromatase inhibitor. Breast Cancer Res. Treat. (1998) 49 (1):S39–S44.
   PubMedGoogle Scholar
• •An interesting discussion of some of the current issues.
   Google Scholar
• JONAT W, HOWELL A, BLOMQVIST C et al.: A randomised trial comparing two doses of the new selective aro-matase inhibitor anastrozole (Arimidex) with meges-trol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer (1996) 32A:404–412.
   PubMed Web of Science ®Google Scholar
• FREUE M, KJAER M, BONI C et al.: Open comparative trial of formestane versus megestrol acetate in postmeno-pausal patients with advanced breast cancer previously treated with tamoxifen. Ciba, Basel AH/BC7, data on file. (1996) (GENERIC) Ref Type: Report
   Google Scholar
• THÜRLIMANN B, PARIDAENS R, ROCHE H et al.: Exemes-tane in postmenopausal pretreated advanced breast cancer: a multicenter Phase II study in patients with aminoglutethimide (AG) failure. Ann. Oncol. (1994) 5 (8):S29.
   PubMedGoogle Scholar
• JONES S, BELT R, COOPER B et al.: A Phase II study of an-titumour efficacy and safety of exemestane (exe) as second-line hormonal treatment of postmenopausal patients with metastatic breast cancer (MBC) refrac-tory to tamoxifen (Tam). Breast Cancer Res. Treat. (1998) 50:304.
   Google Scholar
• JONES S, CHANG A, LUSCH C et al.: A Phase II confirma-tory study of antitumour efficacy and safety of exemes-tane (exe) as third-line hormonal treatment of postmenopausal patients (PTS) with metastatic breast cancer (MBC) refractory to tamoxifen (Tam) and MEGACE'. Breast Cancer Res. Treat. (1998) 50:305. Paul D Taylor & Anthony Howell tAuthor for correspondence CRC Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK Tel.: +44 161 446 3746; Fax: +44 161 446 3299; Email: [email protected]
   Google Scholar